Investigating the expression of miR-29, miR346, miR429 and miR-106b in acute Kidney injury and its relationship with severity disease

Abstract

Acute kidney injury (AKI) is a common and severe syndrome with a high mortality rate in patients admitted to the intensive care unit (ICU). The increasing incidence and lack of reliable biomarkers for early diagnosis of this syndrome have led to many studies in this field. It has been shown that miRNAs can play an essential role in differentiation, development, validation, and therefore as biomarkers for diagnosis. Therefore, the present study aimed to measure the expression of miR-29, miR-346, miR-429, and miR-106b in serum samples of patients with acute renal impairment and its relationship with disease severity by Real-Time RT-PCR and compare control. Methods: According to the study's inclusion and exclusion criteria, 50 blood samples were collected from people with acute kidney damage, and 50 blood samples were selected from healthy individuals. After explaining the importance of the present study and completing the patients' written consent form, blood samples will be collected. The isolated samples are transferred to an RNase inhibitor solution and stored in the refrigerator at -80 ° C to maintain stability. Then, the total RNA of the mentioned sera was extracted. After cDNA synthesis using reverse transcriptase enzyme, the amount of miR-29, miR-346, miR-429, and miR-106b gene markers was determined by Real-time PCR using Master Mix Syber green will be determined in the presence of specific primers. Finally, the relationship between these genes' levels between the two statistical populations of sick and healthy will be compared. Results: Higher levels of serum creatinine, SOFA, and APACHE were found among patients with AKI. APACHE and SOFA scores were significantly increased in patients with AKI compared with healthy individuals. The expression of miR-29 increased significantly (**P<0.01) in both stages. It is also worth noting that the expression of miR-106b, miR-429, miR-100, and miR-346 in stage 2 increased compared to stage1 compared to the healthy group (**P<0.01 in stage 2 and (*P<0.05) in stage1.